In 2022, the bifurcation lesions market was estimated to be worth US$2.25 billion. By the end of 2033, bifurcation lesion device sales are predicted to grow at a compound annual growth rate (CAGR) of 6% and reach a market worth of US$ 4.26 billion.
The availability of therapies tailored to treat lesions close to the coronary bifurcation, patients' increased knowledge of the treatment protocols, and the rise in percutaneous coronary intervention procedures are the main causes of the rising demand for the treatment of coronary bifurcation lesions.
To remain 'ahead' of your competitors, request for a sample: https://www.factmr.com/connectus/sample?flag=S&rep_id=7963
How Are New Entrants Gaining Ground in This Competitive Atmosphere?
"Innovative Medical Solutions Drive New Entrants' Success"
New players in the bifurcation lesions market are leveraging advanced technologies to create smart medical devices, aiming to establish a strong foothold and secure significant revenue shares.
For example, Echopoint Medical, founded in 2018, is at the forefront of developing cutting-edge devices for diagnosing coronary artery disease and microvascular dysfunction. The company specializes in optical-fiber-based cardiac monitoring sensors integrated into medical equipment. One of their key innovations is the iKOs microcatheter, a device embedded with nanomaterials and sensors to detect heart conditions, which can be seamlessly used with cardiovascular devices.
Country-Wise Analysis
The United States maintains a dominant position in the North American bifurcation lesions market due to the presence of prominent industry players, supportive reimbursement policies, and high healthcare spending.
According to the National Center for Health Statistics, coronary artery disease (CAD) accounts for 1 in 4 deaths annually in the U.S., with 785,000 individuals experiencing their first cardiac arrest and 470,000 living with myocardial infarction each year. The establishment of specialized clinics and increased investments in coronary stent innovations are further fueling sales growth in the region.
How Is Demand for Bifurcation Lesion Procedures Evolving in Germany?
Germany’s bifurcation lesion market is projected to grow at a CAGR of 4% from 2023 to 2033. The rising prevalence of heart disorders and the continuous efforts of manufacturers to create advanced gadgets for bifurcation lesions are expected to drive market expansion.
The growth is also supported by Germany's aging population, high prevalence of chronic diseases, and ongoing investments in R&D. These factors are collectively contributing to the increasing demand for bifurcation lesion treatments.
Why Are Coronary Bifurcation Lesion Treatment Procedures Different in Japan and South Korea?
Treatment procedures for coronary bifurcation lesions vary between Japan and South Korea due to differences in how lesion severity is assessed and addressed.
Both countries lead the Asian region in annual coronary procedures and commonly utilize imaging and physiologic guidance. However, the treatment methods differ conceptually.
For instance, a study by the National Center for Biotechnology Information highlights that in Japan, medical professionals rely heavily on imaging guidance before and after percutaneous coronary intervention (PCI) and major artery stenting. In contrast, South Korea frequently employs proximal optimization technique (POT)/re-POT and advanced physiologic assessments like fractional flow reserve (FFR) or instantaneous wave-free ratio (iFR).
These distinct approaches reflect the philosophical differences in coronary bifurcation treatment between the two nations.
Key Segments of Bifurcation Lesions Industry Research
-
By Type :
- One-stent Bifurcation Lesions
- Two-stent Bifurcation Lesions
-
By Application :
- Coronary Vascular
- Peripheral Vascular
-
By Region :
- North America
- Latin America
- Europe
- East Asia
- South Asia & Oceania
- MEA
𝐂𝐨𝐧𝐭𝐚𝐜𝐭:
US Sales Office
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583, +353-1-4434-232
Email: sales@factmr.com
Comments
0 comment